aid: invetx
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/invetx.png
name: Invetx *
description: >-
  Invetx was a Boston-based veterinary biotechnology company developing protein-based
  therapeutics — species-specific, half-life-extended monoclonal antibodies (mAbs) — for
  chronic conditions in companion animals (dogs and cats). Its integrated platform spanned
  antibody discovery, optimization, Fc-variant half-life extension, development and
  manufacturing, with lead program IVX-01. Backed by GV, F-Prime Capital, Novo Holdings,
  Eight Roads, Anterra Capital, Casdin Capital and Tekla, Invetx was acquired by Dechra
  Pharmaceuticals in July 2024 for up to $520M. It exposes no public API, developer, or
  documentation surface, and its standalone website (invetx.com) has been decommissioned
  since the acquisition; this profile is retained as a network lead / portfolio record.
url: https://raw.githubusercontent.com/api-evangelist/invetx/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- gv
x-tier: stub
x-tier-reason: portfolio-lead
x-status: acquired
x-acquired-by: dechra
x-acquired-date: '2024-07-18'
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Life Sciences
- Biotechnology
- Animal Health
- Veterinary
- Monoclonal Antibodies
- Therapeutics
- Acquired
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/invetx-domain-security.yml
- type: Website
  url: invetx.com
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence